Financials Nanalysis Scientific Corp.
Equities
NSCI
CA63000Y1034
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.475 CAD | 0.00% | +7.95% | +26.67% |
04-30 | Transcript : Nanalysis Scientific Corp., 2023 Earnings Call, Apr 30, 2024 | |
04-29 | Nanalysis Scientific Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Capitalization 1 | 31.37 | 111.4 | 68.83 | 38.08 | 53.69 |
Enterprise Value (EV) 1 | 31.37 | 111.4 | 68.83 | 38.08 | 53.69 |
P/E ratio | -7.92 x | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 6.94 x | 2.77 x | 1.34 x | 1.57 x |
EV / Revenue | - | 6.94 x | 2.77 x | 1.34 x | 1.57 x |
EV / EBITDA | - | 58.5 x | -17.5 x | -4.72 x | -21.5 x |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | 4.68 x | - | - | - |
Nbr of stocks (in thousands) | 66,035 | 76,829 | 94,282 | 101,544 | 113,027 |
Reference price 2 | 0.4750 | 1.450 | 0.7300 | 0.3750 | 0.4750 |
Announcement Date | 21-04-22 | 22-04-28 | 23-04-27 | 24-04-29 | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net sales 1 | - | 16.04 | 24.82 | 28.47 | 34.1 |
EBITDA 1 | - | 1.905 | -3.935 | -8.074 | -2.5 |
EBIT | - | - | - | - | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -3.678 | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | -0.0600 | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 21-04-22 | 22-04-28 | 23-04-27 | 24-04-29 | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 3.336 | 5.077 | 5.554 | 5.187 | 6.878 | 7.203 | 4.674 | 6.956 | 7.036 | 9.8 | 7.4 | 7.2 | 8.6 | 10.9 |
EBITDA 1 | 0.012 | 0.413 | 0.21 | -0.947 | -0.618 | -2.58 | -3.547 | -2.399 | -1.354 | -0.774 | -1.2 | -0.7 | -0.3 | 0.1 |
EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21-11-18 | 22-04-28 | 22-05-30 | 22-08-25 | 22-11-29 | 23-04-27 | 23-05-25 | 23-08-24 | 23-11-29 | 24-04-29 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | -9.25% | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets | - | - | - | - | - |
Book Value Per Share | - | 0.3100 | - | - | - |
Cash Flow per Share | - | -0.0200 | - | - | - |
Capex | - | 0.6 | - | - | - |
Capex / Sales | - | 3.71% | - | - | - |
Announcement Date | 21-04-22 | 22-04-28 | 23-04-27 | 24-04-29 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.67% | 39.23M | |
+11.59% | 221B | |
+9.40% | 186B | |
+14.69% | 137B | |
+27.45% | 109B | |
-0.04% | 63.09B | |
+14.03% | 52.68B | |
+4.86% | 50.86B | |
+7.75% | 42.53B | |
+7.42% | 37.76B |
- Stock Market
- Equities
- NSCI Stock
- Financials Nanalysis Scientific Corp.